{"DataElement":{"publicId":"3187293","version":"1","preferredName":"Radiation Therapy Oncology Group Acute Effect Adverse Event Name","preferredDefinition":"Text name for an acute morbidity event, using criteria from the Radiation Therapy Oncology Group (RTOG) to score/grade adverse events from radiation therapy.","longName":"RTOG_AC_EFF_AE_NM","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"3187281","version":"1","preferredName":"Radiation Therapy Oncology Group CTCAE Acute Side Effect","preferredDefinition":"The Radiation Therapy Oncology Group (RTOG) is a multi-institutional cooperative organization, a national cancer study research group comprised of 250 of the major research institutions nationally and in Canada, funded by NCI, headquartered in Philadelphia with almost 30 years of experience in running clinical trials. More than 40 clinical trials that involve radiation therapy either alone or in conjunction with surgery and/or chemotherapeutic drugs are active at any one time within RTOG. The group is interested in quality of life issues and their effects on the cancer patient__A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.._Having a severe and rapid onset of symptoms with short duration. (NCI)_An unwanted side effect of treatment.","longName":"RTOG_CTCAE_AC_EFF","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"3187275","version":"1","preferredName":"Radiation Therapy Oncology Group Common Terminology Criteria for Adverse Events","preferredDefinition":"The Radiation Therapy Oncology Group (RTOG) is a multi-institutional cooperative organization, a national cancer study research group comprised of 250 of the major research institutions nationally and in Canada, funded by NCI, headquartered in Philadelphia with almost 30 years of experience in running clinical trials. More than 40 clinical trials that involve radiation therapy either alone or in conjunction with surgery and/or chemotherapeutic drugs are active at any one time within RTOG. The group is interested in quality of life issues and their effects on the cancer patient:A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C19778:C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy Oncology Group","conceptCode":"C19778","definition":"A multi-institutional cooperative organization, a national cancer study research group comprised of 250 of the major research institutions nationally and in Canada, funded by NCI, headquartered in Philadelphia with almost 30 years of experience in running clinical trials. More than 40 clinical trials that involve radiation therapy either alone or in conjunction with surgery and/or chemotherapeutic drugs are active at any one time within RTOG. The group is interested in quality of life issues and their effects on the cancer patient","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AC65E5B-B5AA-5617-E040-BB89AD43498C","latestVersionIndicator":"Yes","beginDate":"2011-01-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-01-26","modifiedBy":"ONEDATA","dateModified":"2011-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3187279","version":"1","preferredName":"Acute Side Effect","preferredDefinition":"Having a severe and rapid onset of symptoms with short duration. (NCI):An unwanted side effect of treatment.","longName":"C14140:C2861","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute","conceptCode":"C14140","definition":"Having a severe and rapid onset of symptoms with short duration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Side Effect","conceptCode":"C2861","definition":"The term was used in various ways in the past, to describe unintended effects of medical intervention, usually negative (unfavourable), but also positive (favourable) ones. It is recommended that this term no longer be used and particularly should not be regarded as synonymous with adverse event or adverse reaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AC65E5B-B5DD-5617-E040-BB89AD43498C","latestVersionIndicator":"Yes","beginDate":"2011-01-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-01-26","modifiedBy":"ONEDATA","dateModified":"2011-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AC65E5B-B5EE-5617-E040-BB89AD43498C","latestVersionIndicator":"Yes","beginDate":"2011-01-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-01-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3187287","version":"1","preferredName":"Radiation Therapy Oncology Group Acute Adverse Event Name","preferredDefinition":"The Radiation Therapy Oncology Group (RTOG) is a multi-institutional cooperative organization, a national cancer study research group comprised of 250 of the major research institutions nationally and in Canada, funded by NCI, headquartered in Philadelphia with almost 30 years of experience in running clinical trials. More than 40 clinical trials that involve radiation therapy either alone or in conjunction with surgery and/or chemotherapeutic drugs are active at any one time within RTOG. The group is interested in quality of life issues and their effects on the cancer patient_Having a severe and rapid onset of symptoms with short duration. (NCI)_Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used.","longName":"RTOG_AE_AC_EFF_NM","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"40","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Skin","valueDescription":"Skin","ValueMeaning":{"publicId":"2816295","version":"1","preferredName":"Skin","longName":"2816295","preferredDefinition":"1. An organ and the enveloping membrane of the body; includes, in addition to the epidermis and dermis, all of the derivatives of the epidermis, e.g., hairs, nails, sudoriferous and sebaceous glands, and mammary glands. Subdivisions of the skin surround various body parts; as a whole, the skin constitutes the external surface of the body. 2. The rind, capsule, or covering of any body or part.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin","conceptCode":"C12470","definition":"An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E266FBD-287B-AD47-E040-BB89A64327A4","latestVersionIndicator":"Yes","beginDate":"2008-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9AC65E5B-B721-5617-E040-BB89AD43498C","beginDate":"2011-01-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-01-26","modifiedBy":"ONEDATA","dateModified":"2011-01-26","deletedIndicator":"No"},{"value":"Neutrophils","valueDescription":"Neutrophil","ValueMeaning":{"publicId":"2780131","version":"1","preferredName":"Neutrophil","longName":"2780131","preferredDefinition":"Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neutrophil","conceptCode":"C12533","definition":"Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5615FFC6-BECB-6405-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9AC65E5B-B791-5617-E040-BB89AD43498C","beginDate":"2011-01-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-01-26","modifiedBy":"ONEDATA","dateModified":"2011-01-26","deletedIndicator":"No"},{"value":"Genitourinary","valueDescription":"Genitourinary","ValueMeaning":{"publicId":"2957617","version":"1","preferredName":"Genitourinary","longName":"2957617","preferredDefinition":"Of or related to the genital and urinary organs or their functions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Genitourinary","conceptCode":"C25350","definition":"Of or related to the genital and urinary organs or their functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"775D6DFA-A9B9-76E6-E040-BB89AD432C79","latestVersionIndicator":"Yes","beginDate":"2009-11-02","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-11-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9AC65E5B-B7DE-5617-E040-BB89AD43498C","beginDate":"2011-01-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-01-26","modifiedBy":"ONEDATA","dateModified":"2011-01-26","deletedIndicator":"No"},{"value":"Lower G.I. Including Pelvis","valueDescription":"Lower Gastrointestinal Tract","ValueMeaning":{"publicId":"3143267","version":"1","preferredName":"Lower Gastrointestinal Tract","longName":"3143267","preferredDefinition":"The lower part of the gastrointestinal tract that includes the jejunum and ileum of the small intestine and the large intestine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lower Gastrointestinal Tract","conceptCode":"C33010","definition":"The lower part of the gastrointestinal tract that includes the jejunum and ileum of the small intestine and the large intestine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91418E26-DEB4-630D-E040-BB89AD43707D","latestVersionIndicator":"Yes","beginDate":"2010-09-27","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-09-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9AC65E5B-B7F3-5617-E040-BB89AD43498C","beginDate":"2011-01-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-01-26","modifiedBy":"ONEDATA","dateModified":"2011-01-26","deletedIndicator":"No"},{"value":"Upper G.I.","valueDescription":"Upper Gastrointestinal Tract","ValueMeaning":{"publicId":"3143268","version":"1","preferredName":"Upper Gastrointestinal Tract","longName":"3143268","preferredDefinition":"The upper part of the gastrointestinal tract that includes the esophagus, stomach, and duodenum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Upper Gastrointestinal Tract","conceptCode":"C33837","definition":"The upper part of the gastrointestinal tract that includes the esophagus, stomach, and duodenum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91418E26-DED9-630D-E040-BB89AD43707D","latestVersionIndicator":"Yes","beginDate":"2010-09-27","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-09-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9AC65E5B-B808-5617-E040-BB89AD43498C","beginDate":"2011-01-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-01-26","modifiedBy":"ONEDATA","dateModified":"2011-01-26","deletedIndicator":"No"},{"value":"Brain/CNS","valueDescription":"Central Nervous System","ValueMeaning":{"publicId":"5343369","version":"1","preferredName":"Central Nervous System","longName":"5343369","preferredDefinition":"The part of the nervous system that consists of the brain, spinal cord, and meninges.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System","conceptCode":"C12438","definition":"The part of the nervous system that consists of the brain, spinal cord, and meninges.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37781D63-9917-FF48-E050-BB89AD433A9A","latestVersionIndicator":"Yes","beginDate":"2016-07-12","endDate":null,"createdBy":"DWARZEL","dateCreated":"2016-07-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"37781D63-992F-FF48-E050-BB89AD433A9A","beginDate":"2016-07-12","endDate":null,"createdBy":"DWARZEL","dateCreated":"2016-07-12","modifiedBy":"ONEDATA","dateModified":"2016-07-12","deletedIndicator":"No"},{"value":"Hematocrit (%)","valueDescription":"Hematocrit","ValueMeaning":{"publicId":"2833092","version":"1","preferredName":"Hematocrit","longName":"2833092","preferredDefinition":"A measure of the volume of red blood cells expressed as a percentage of the total blood volume. Normal in males is 43-49%, in females 37-43%.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematocrit Measurement","conceptCode":"C64796","definition":"A measure of the volume of red blood cells expressed as a percentage of the total blood volume. Normal in males is 43-49%, in females 37-43%.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"621D07D9-01BF-271C-E040-BB89AD43153D","latestVersionIndicator":"Yes","beginDate":"2009-02-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-02-04","modifiedBy":"COLBERTM","dateModified":"2023-06-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3776D628-80A5-FDB2-E050-BB89AD437DA5","beginDate":"2011-01-26","endDate":null,"createdBy":"DWARZEL","dateCreated":"2016-07-12","modifiedBy":"SBR","dateModified":"2016-07-14","deletedIndicator":"No"},{"value":"Hematologic WBC (X 1000)","valueDescription":"Leukocytes or White Blood Cells","ValueMeaning":{"publicId":"2579443","version":"1","preferredName":"Leukocytes or White Blood Cells","longName":"2579443","preferredDefinition":"White blood cells. These include granular leukocytes (BASOPHILS, EOSINOPHILS, and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukocyte","conceptCode":"C12529","definition":"Blood cells that are devoid of hemoglobin, capable of ameboid motion and phagocytosis, and act as the principal components of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0360-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-06-02","modifiedBy":"REEVESD","dateModified":"2011-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3776D628-80B9-FDB2-E050-BB89AD437DA5","beginDate":"2011-01-26","endDate":null,"createdBy":"DWARZEL","dateCreated":"2016-07-12","modifiedBy":"SBR","dateModified":"2016-07-18","deletedIndicator":"No"},{"value":"Hemoglobin (Gm%)","valueDescription":"Hemoglobin","ValueMeaning":{"publicId":"3187288","version":"1","preferredName":"Hemoglobin","longName":"3187288","preferredDefinition":"The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemoglobin","conceptCode":"C16676","definition":"The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AC65E5B-B764-5617-E040-BB89AD43498C","latestVersionIndicator":"Yes","beginDate":"2011-01-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-01-26","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3776D628-80CD-FDB2-E050-BB89AD437DA5","beginDate":"2011-01-26","endDate":null,"createdBy":"DWARZEL","dateCreated":"2016-07-12","modifiedBy":"SBR","dateModified":"2016-07-14","deletedIndicator":"No"},{"value":"Platelets (X 1000)","valueDescription":"Platelet","ValueMeaning":{"publicId":"3187289","version":"1","preferredName":"Platelet","longName":"3187289","preferredDefinition":"platelet. An irregularly shaped disklike cytoplasmic fragment of a megakaryocyte that is shed in the marrow sinus and subsequently found in the peripheral blood where it functions in clotting. A platelet contains granules in the central part (granulomere) and, peripherally, clear protoplasm (hyalomere), but no definite nucleus; is about one-third to one-half the size of an erythrocyte; and contains no hemoglobin. (STED98)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Platelet","conceptCode":"C12520","definition":"An irregular, disc-shaped element in the blood that assists in blood clotting. Platelets are not blood cells, they are fragments of large bone marrow cells called megakaryocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AC65E5B-B79C-5617-E040-BB89AD43498C","latestVersionIndicator":"Yes","beginDate":"2011-01-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-01-26","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":"9/20/22 Changed PV in Biomarker Name VD to Platelet (was previously Platelet Count, which is C51951). Then made a new Platelet Count PV for Biomarker Name VD. mr;","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3776D628-80E1-FDB2-E050-BB89AD437DA5","beginDate":"2011-01-26","endDate":null,"createdBy":"DWARZEL","dateCreated":"2016-07-12","modifiedBy":"SBR","dateModified":"2016-07-14","deletedIndicator":"No"},{"value":"Eye","valueDescription":"Eye","ValueMeaning":{"publicId":"2750131","version":"1","preferredName":"Eye","longName":"2750131","preferredDefinition":"The organ of sight or vision.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eye","conceptCode":"C12401","definition":"The organ of sight or vision.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D5F17A1-895B-40B7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-16","modifiedBy":"COOPERM","dateModified":"2018-04-05","changeDescription":"Updated concept definition to use current NCIt. 4.5.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3776D628-80ED-FDB2-E050-BB89AD437DA5","beginDate":"2016-07-12","endDate":null,"createdBy":"DWARZEL","dateCreated":"2016-07-12","modifiedBy":"ONEDATA","dateModified":"2016-07-12","deletedIndicator":"No"},{"value":"Ear","valueDescription":"Ear","ValueMeaning":{"publicId":"4265331","version":"1","preferredName":"Ear","longName":"4265331","preferredDefinition":"A sense organ needed for the detection of sound and for establishing balance. The outer ear consists of the auricle, the ear canal as well as the tympanic membrane. The middle ear is made up of an air-filled cavity behind the tympanic membrane that contains the ossicles (malleus, incus and stapes). The inner ear is made up of the cochlea needed for hearing and the vestibular apparatus required for balance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ear","conceptCode":"C12394","definition":"A sense organ needed for the detection of sound and for establishing balance. The outer ear consists of the auricle, the ear canal as well as the tympanic membrane. The middle ear is made up of an air-filled cavity behind the tympanic membrane that contains the ossicles (malleus, incus and stapes). The inner ear is made up of the cochlea needed for hearing and the vestibular apparatus required for balance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F694966F-2EF1-D003-E040-BB89AD430DBC","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3776D628-80F8-FDB2-E050-BB89AD437DA5","beginDate":"2016-07-12","endDate":null,"createdBy":"DWARZEL","dateCreated":"2016-07-12","modifiedBy":"ONEDATA","dateModified":"2016-07-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3187286","version":"1","preferredName":"Radiation Therapy Oncology Group Acute Adverse Event Name","preferredDefinition":"The Radiation Therapy Oncology Group (RTOG) is a multi-institutional cooperative organization, a national cancer study research group comprised of 250 of the major research institutions nationally and in Canada, funded by NCI, headquartered in Philadelphia with almost 30 years of experience in running clinical trials. More than 40 clinical trials that involve radiation therapy either alone or in conjunction with surgery and/or chemotherapeutic drugs are active at any one time within RTOG. The group is interested in quality of life issues and their effects on the cancer patient:Having a severe and rapid onset of symptoms with short duration. (NCI):Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used.:The words or language units by which a thing is known.","longName":"C19778:C14140:C41331:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy Oncology Group","conceptCode":"C19778","definition":"A multi-institutional cooperative organization, a national cancer study research group comprised of 250 of the major research institutions nationally and in Canada, funded by NCI, headquartered in Philadelphia with almost 30 years of experience in running clinical trials. More than 40 clinical trials that involve radiation therapy either alone or in conjunction with surgery and/or chemotherapeutic drugs are active at any one time within RTOG. The group is interested in quality of life issues and their effects on the cancer patient","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Acute","conceptCode":"C14140","definition":"Having a severe and rapid onset of symptoms with short duration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Adverse Event","conceptCode":"C41331","definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AC65E5B-B6FC-5617-E040-BB89AD43498C","latestVersionIndicator":"Yes","beginDate":"2011-01-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-01-26","modifiedBy":"ONEDATA","dateModified":"2011-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTCAEv4.0:Common Terminology Criteria for Adverse Events v4.0","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AC65E5B-B70D-5617-E040-BB89AD43498C","latestVersionIndicator":"Yes","beginDate":"2011-01-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-01-26","modifiedBy":"SBR","dateModified":"2016-07-18","changeDescription":"Updated to add new values for RTOG per Dianne Reeves. Have to remove special characters, update VD, then run script to reinsert special characters DW 07-12-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Acute RTOG Toxicity","type":"Preferred Question Text","description":"Acute RTOG Toxicity","url":null,"context":"CCR"}],"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AC6E59A-97DC-5F20-E040-BB89AD436844","latestVersionIndicator":"Yes","beginDate":"2011-01-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-01-26","modifiedBy":"REEVESD","dateModified":"2016-07-12","changeDescription":"Curated for CCR clinical trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}